“Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor DNA. In this video, Jens Lohr, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA, highlights the advantages of this. Dr Lohr also addresses the limitation of liquid biopsies, including patient selection and standardization. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
“
Liquid biopsies for multiple myeloma: the attractions and limits
